
On Wednesday, Danish medtech firm Ambu announced preliminary financial figures from the third quarter of fiscal 2021/2022 – alongside a guidance downgrade for the full-year and a cost reduction program meant to result in DKK 250m (USD 34.1m) annualized savings.
Ambu generated DKK 1.1bn (USD 150.2m) in sales in the three-month period, booking an operating profit (EBIT before special items) of DKK 42m (USD 5.7m). Organic growth amounted to 6% in July, which Ambu notes is ”significantly below [the firm’s] expectations.”
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app